RxCell Inc. Granted U.S. Patent for iPSC-based Cell Therapy

PARK CITY, Utah--(BUSINESS WIRE)--RxCell Inc. is pleased to announce the issuance of U.S. Patent 11,946,069 entitled "Method for Generating Multiple Cellular Products from Single Pluripotent Cell Source", a significant advancement in the field of regenerative medicine. This patent, granted on April 2, 2024, provides RxCell with exclusive rights to induced pluripotent stem cell (iPSC)-derived cells for therapy across a broad spectrum of diseases. Advancing Cell Replacement Therapy The potential